1/14
08:18 am
rprx
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
Low
Report
Teva Is No Longer A Turnaround Story, It's A Growth One [Seeking Alpha]
1/13
06:33 am
rprx
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
Low
Report
TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug [Yahoo! Finance]
1/12
07:15 am
rprx
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/12
01:38 am
rprx
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
Low
Report
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment [Seeking Alpha]
1/11
05:15 pm
rprx
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
Low
Report
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
1/9
08:30 am
rprx
Royalty Pharma Announces Dividend Increase
Low
Report
Royalty Pharma Announces Dividend Increase
1/8
11:51 pm
rprx
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
Low
Report
Is Royalty Pharma (RPRX) Pricing Reflect Its Strong 1 Year Share Price Performance [Yahoo! Finance]
12/29
08:21 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones [Yahoo! Finance]
12/29
04:40 pm
rprx
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
Low
Report
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones
12/16
08:08 am
rprx
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
Medium
Report
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln [Seeking Alpha]
12/16
07:15 am
rprx
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
Low
Report
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million
12/11
02:10 pm
rprx
Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.
Low
Report
Royalty Pharma (NASDAQ:RPRX) was given a new $45.00 price target on by analysts at Leerink Partners.
12/11
11:48 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its price target raised by analysts at TD Cowen from $42.00 to $45.00. They now have a "buy" rating on the stock.
12/11
10:04 am
rprx
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/5
06:16 am
rprx
Denali makes $275m funding agreement with Royalty Pharma [Yahoo! Finance]
Low
Report
Denali makes $275m funding agreement with Royalty Pharma [Yahoo! Finance]
12/5
05:43 am
rprx
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement [Yahoo! Finance]
Low
Report
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement [Yahoo! Finance]
12/4
07:10 am
rprx
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
Low
Report
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
12/3
06:18 pm
rprx
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Medium
Report
Royalty Pharma plc (RPRX) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
11/29
12:31 am
rprx
Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at
Wall Street Z
Low
Report
Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at
Wall Street Z
11/26
09:15 am
rprx
Royalty Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Royalty Pharma to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/26
08:15 am
rprx
Royalty Pharma to Present at Upcoming Investor Conferences
Low
Report
Royalty Pharma to Present at Upcoming Investor Conferences
11/19
06:53 am
rprx
Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "hold" rating.
Medium
Report
Royalty Pharma (NASDAQ:RPRX) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "hold" rating.
11/18
04:36 pm
rprx
How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves [Yahoo! Finance]
Medium
Report
How Analyst Views on Royalty Pharma Are Shifting With Recent Acquisition and Growth Moves [Yahoo! Finance]
11/17
07:42 am
rprx
3 Low-Volatility Stocks We Find Risky [Yahoo! Finance]
Low
Report
3 Low-Volatility Stocks We Find Risky [Yahoo! Finance]
11/15
07:13 am
rprx
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated [Seeking Alpha]
Neutral
Report
Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated [Seeking Alpha]